文献速递疼痛医学

神经毁损性内脏神经阻滞对不可切除胰腺癌疼痛、生存与生活质量的影响:随机对照试验

Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial.
PubMed 文献 · Anesthesiology · 2021-01-01

结果显示神经毁损组前3个月疼痛缓解更优、前5个月阿片类药物用量更少,但总生存期存在显著差异,IV期患者神经毁损组生存期缩短,生活质量无差异。

要点

  • 神经毁损性内脏神经阻滞可改善前3个月疼痛并减少前5个月阿片用量
  • 总生存期组间存在显著差异,IV期患者神经毁损组生存期缩短
  • 生活质量未见差异,需权衡疼痛获益与IV期患者生存风险

核心结论

  • 神经毁损性内脏神经阻滞似乎是控制不可切除胰腺癌疼痛和减少阿片需求的的有效选择。
  • 但神经毁损组总生存期存在显著差异,IV期患者生存期缩短,生活质量无差异。

研究设计与样本

  • 随机、双盲、平行臂试验,在中国五个中心开展。
  • 试验组接受无水酒精内脏神经毁损阻滞,对照组接受生理盐水注射。
  • 随访8个月或直至死亡。

主要发现

  • 神经毁损组前3个月疼痛缓解优于安慰剂注射,第1个月最显著(平均差0.7,95%CI 0.3-1.0,校正P<0.001)。
  • 神经毁损组前5个月阿片类药物消耗低于安慰剂注射,第1个月最显著(平均差95.8,95%CI 67.4-124.1,校正P<0.001)。
  • 组间总生存期存在显著差异(风险比1.56,95%CI 1.03-2.35,P=0.036)。
  • IV期患者神经毁损组生存期显著缩短(风险比1.94,95%CI 1.29-2.93,P=0.001),III期患者无显著差异(风险比1.08,95%CI 0.59-1.97,P=0.809)。
  • 生活质量未见差异。

临床怎么用

  • 对于不可切除胰腺癌伴中重度疼痛患者,可考虑神经毁损性内脏神经阻滞以改善短期疼痛并减少阿片用量。
  • 在IV期患者中应用需谨慎评估生存风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurolytic splanchnic nerve block is used to manage pancreatic cancer pain. However, its impact on survival and quality of life remains controversial. The authors' primary hypothesis was that pain relief would be better with a nerve block. Secondarily, they hypothesized that analgesic use, survival, and quality of life might be affected. METHODS: This randomized, double-blind, parallel-armed trial was conducted in five Chinese centers. Eligible patients suffering from moderate to severe pain conditions were randomly assigned to receive splanchnic nerve block with either absolute alcohol (neurolysis) or normal saline (control). The primary outcome was pain relief measured on a visual analogue scale. Opioid consumption, survival, quality of life, and adverse effects were also documented. Analgesics were managed using a protocol common to all centers. Patients were followed up for 8 months or until death. RESULTS: Ninety-six patients (48 for each group) were included in the analysis. Pain relief with neurolysis was greater for the first 3 months (largest at the first month; mean difference, 0.7 [95% CI, 0.3 to 1.0]; adjusted P < 0.001) compared with placebo injection. Opioid consumption with neurolysis was lower for the first 5 months (largest at the first month; mean difference, 95.8 [95% CI, 67.4 to 124.1]; adjusted P < 0.001) compared with placebo injection. There was a significant difference in survival (hazard ratio, 1.56 [95% CI, 1.03 to 2.35]; P = 0.036) between groups. A significant reduction in survival in neurolysis was found for stage IV patients (hazard ratio, 1.94 [95% CI, 1.29 to 2.93]; P = 0.001), but not for stage III patients (hazard ratio, 1.08 [95% CI, 0.59 to 1.97]; P = 0.809). No differences in quality of life were observed. CONCLUSIONS: Neurolytic splanchnic nerve block appears to be an effective option for controlling pain and reducing opioid requirements in patients with unresectable pancreatic cancer.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Dong D, Zhao M, Zhang J, et al. Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial. Anesthesiology. 2021. PMID: 34398950. doi:10.1097/ALN.0000000000003936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。